RKVTF
Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets. The company's preclinical product pipeline include kt-2000AI, an poly(ADP)-ribose polymerase (PARP) brain penetrant cancer therapy; kt-3000, a bi-functional small-molecule drug candidate; kt-3283 series … Read more
RKVTF (RKVTF) - Net Assets
Latest net assets as of September 2025: $1.89 Million USD
Based on the latest financial reports, RKVTF (RKVTF) has net assets worth $1.89 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.27 Million) and total liabilities ($3.38 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.89 Million |
| % of Total Assets | 35.84% |
| Annual Growth Rate | -20.46% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 24.75 |
RKVTF - Net Assets Trend (2021–2024)
This chart illustrates how RKVTF's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for RKVTF (2021–2024)
The table below shows the annual net assets of RKVTF from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-09-30 | $4.30 Million | +17.46% |
| 2023-09-30 | $3.66 Million | -39.14% |
| 2022-09-30 | $6.01 Million | -29.62% |
| 2021-09-30 | $8.54 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to RKVTF's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 947677700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $19.30 Million | 448.88% |
| Total Equity | $4.30 Million | 100.00% |
RKVTF Competitors by Market Cap
The table below lists competitors of RKVTF ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tri Banyan Tirta Tbk
JK:ALTO
|
$1.09 Million |
|
Wang-Zheng Bhd
KLSE:7203
|
$1.09 Million |
|
HARTFORD FIN SERV
BE:HFF
|
$1.09 Million |
|
VHAI
BATS:VHAI
|
$1.09 Million |
|
Integritas Viager SA
PA:MLVIE
|
$1.09 Million |
|
Qiiwi Games AB (publ)
ST:QIIWI
|
$1.09 Million |
|
Globe Kita Terang Tbk PT
JK:GLOB
|
$1.09 Million |
|
Hong Yuan Holding Group
PINK:HGYN
|
$1.09 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in RKVTF's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,659,836 to 4,298,915, a change of 639,079 (17.5%).
- Net loss of 4,072,618 reduced equity.
- New share issuances of 4,920,000 increased equity.
- Other factors decreased equity by 208,303.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-4.07 Million | -94.74% |
| Share Issuances | $4.92 Million | +114.45% |
| Other Changes | $-208.30K | -4.85% |
| Total Change | $- | 17.46% |
Book Value vs Market Value Analysis
This analysis compares RKVTF's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.26x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.49x to 1.26x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-09-30 | $0.12 | $0.06 | x |
| 2022-09-30 | $0.09 | $0.06 | x |
| 2023-09-30 | $0.05 | $0.06 | x |
| 2024-09-30 | $0.05 | $0.06 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently RKVTF utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -94.74%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.45x
- Recent ROE (-94.74%) is below the historical average (-69.29%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -64.62% | 0.00% | 0.00x | 1.01x | $-6.38 Million |
| 2022 | -46.41% | 0.00% | 0.00x | 1.02x | $-3.39 Million |
| 2023 | -71.39% | 0.00% | 0.00x | 1.41x | $-2.98 Million |
| 2024 | -94.74% | 0.00% | 0.00x | 1.45x | $-4.50 Million |
Industry Comparison
This section compares RKVTF's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| RKVTF (RKVTF) | $1.89 Million | -64.62% | 1.79x | $1.09 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |